TY - JOUR
T1 - Current Clinical Utility of Circulating Tumor DNA Testing in Breast Cancer
T2 - A Practical Approach
AU - Xi, Jing
AU - Ma, Cynthia X.
AU - O’Shaughnessy, Joyce
N1 - Publisher Copyright:
© 2024 by American Society of Clinical Oncology.
PY - 2024/11/1
Y1 - 2024/11/1
N2 - Circulating tumor DNA (ctDNA) refers to DNA fragments released from cancer cells into the bloodstream. Clinical utility of ctDNA in breast cancer has been explored in both metastatic breast cancer (MBC) and early-stage breast cancer (EBC) settings. In MBC, ctDNA can detect therapeutically targetable genomic alterations and has shown great potential in predicting treatment response or resistance. Accumulating data suggest that ctDNA might also have prognostic value in MBC. In EBC, emerging data have shown ctDNA’s predictive and/or prognostic value in both neoadjuvant and adjuvant settings. Minimal residual disease (MRD) detection via ctDNA to detect clinical recurrence after curative therapy is a rapidly advancing field. In this review, we discuss the existing and emerging data regarding ctDNA utility in both MBC and EBC settings.
AB - Circulating tumor DNA (ctDNA) refers to DNA fragments released from cancer cells into the bloodstream. Clinical utility of ctDNA in breast cancer has been explored in both metastatic breast cancer (MBC) and early-stage breast cancer (EBC) settings. In MBC, ctDNA can detect therapeutically targetable genomic alterations and has shown great potential in predicting treatment response or resistance. Accumulating data suggest that ctDNA might also have prognostic value in MBC. In EBC, emerging data have shown ctDNA’s predictive and/or prognostic value in both neoadjuvant and adjuvant settings. Minimal residual disease (MRD) detection via ctDNA to detect clinical recurrence after curative therapy is a rapidly advancing field. In this review, we discuss the existing and emerging data regarding ctDNA utility in both MBC and EBC settings.
UR - http://www.scopus.com/inward/record.url?scp=85209475626&partnerID=8YFLogxK
U2 - 10.1200/OP.24.00274
DO - 10.1200/OP.24.00274
M3 - Review article
C2 - 39531841
AN - SCOPUS:85209475626
SN - 2688-1527
VL - 20
SP - 1460
EP - 1470
JO - JCO Oncology Practice
JF - JCO Oncology Practice
IS - 11
ER -